These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11062950)

  • 1. [Marked creatine-phosphokinase elevation in myopathy after treatment with bezafibrate].
    Slobodin G; Yeshurun D
    Harefuah; 2000 Sep; 139(5-6):193-5, 246. PubMed ID: 11062950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acute severe myositis due to bezafibrate treatment].
    Yeshurun D; Dakak N; Khoury K; Daher E
    Harefuah; 1989 Mar; 116(5):261-3. PubMed ID: 2722079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.
    Kamaliah MD; Sanjay LD
    Singapore Med J; 2001 Aug; 42(8):368-72. PubMed ID: 11764054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
    McClure DL; Valuck RJ; Glanz M; Murphy JR; Hokanson JE
    J Clin Epidemiol; 2007 Aug; 60(8):812-8. PubMed ID: 17606177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate].
    Sugie M; Kuriki A; Arai D; Ichikawa H; Kawamura M
    No To Shinkei; 2005 Sep; 57(9):785-90. PubMed ID: 16248366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerance of 400 MG bezafibrate in diabetic and hyperlipidaemic patients.
    Lakatos J; Molnár M; Tóth K
    Acta Physiol Hung; 1996; 84(4):433-5. PubMed ID: 9328624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD.
    Yang KC; Fang CC; Su TC; Lee YT
    Am J Kidney Dis; 2005 Mar; 45(3):e57-60. PubMed ID: 15754265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bezafibrate myopathy in two patients with chronic renal failure].
    Inoue M; Jimi T; Machida H; Niwa Y; Wakayama Y
    Rinsho Shinkeigaku; 1992 Jul; 32(7):725-8. PubMed ID: 1291164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine elevation with fibrates: is it a class effect?
    Harats D; Yodfat O; Doolman R; Gavendo S; Marko D; Shaish A; Sela BA
    Isr Med Assoc J; 2001 Apr; 3(4):243-6. PubMed ID: 11344833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.
    Tahmaz M; Kumbasar B; Ergen K; Ure U; Karatemiz G; Kazancioglu R
    Ren Fail; 2007; 29(7):927-30. PubMed ID: 17994463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bezafibrates cause moderate, reversible impairment in renal function in patients without prior renal disease.
    Charach G; Grosskopf I; Rotmensch HH; Kitzis I; Weintraub M
    Nephron Clin Pract; 2005; 100(4):c120-5. PubMed ID: 15849478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term bezafibrate treatment in a lipid clinic].
    Yeshurun D; Abukarshin R; Ellias N; Naschitz JE
    Harefuah; 1992 May; 122(10):632-4, 687. PubMed ID: 1526540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myotoxicity associated with lipid-lowering drugs.
    Baer AN; Wortmann RL
    Curr Opin Rheumatol; 2007 Jan; 19(1):67-73. PubMed ID: 17143099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
    Ushiroyama T; Sakuma K; Nosaka S
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):142-8. PubMed ID: 16891292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.
    Williams AJ; Baker F; Walls J
    Br J Clin Pharmacol; 1984 Sep; 18(3):361-7. PubMed ID: 6386024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
    Nichols GA; Koro CE
    Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE; Sowell MO; Stender M; Qizilbash N
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
    Taniguchi A; Fukushima M; Sakai M; Tokuyama K; Nagata I; Fukunaga A; Kishimoto H; Doi K; Yamashita Y; Matsuura T; Kitatani N; Okumura T; Nagasaka S; Nakaishi S; Nakai Y
    Metabolism; 2001 Apr; 50(4):477-80. PubMed ID: 11288046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.